Physician profile
James Knapp
NPI 1033208145
$1,191.33
in general payments reported to CMS, 2019-2025
21 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $143 · 2024: $69.72 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $317.02 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $178.13 | 2019-2025 | Airsupra |
| Lilly USA, LLC | $161.50 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.75 | 2019-2025 | Jardiance |
| Pfizer INC. | $110.14 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $96.25 | 2019-2020 | |
| Amgen INC. | $83.70 | 2019-2025 | Evenity, Prolia |
| Allergan, INC. | $62.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.15 | 2019-2020 | |
| Hologic Sales and Service, LLC | $42.06 | 2019-2025 | Aptima |
| Novo Nordisk INC | $41.04 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $35.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $25.02 | 2019 | |
| Abbott Laboratories | $22.90 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $22.42 | 2019-2020 | |
| Lundbeck LLC | $22.24 | 2024 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $21.21 | 2019 | |
| Axsome Therapeutics, INC. | $20.94 | 2025 | Auvelity |
| Genentech USA, INC. | $20.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.88 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.